| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
2 This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, relating to our business, operations, and financial conditions, in... |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 |
| 07 Jul 2026 |
8-K: Other Events
On July 7, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the Company entered into a research collaboration and license agreement (the “Agreement”) with Remagine Labs, Inc., a developer of electronically controlled... |
| 02 Jul 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Form 8-K dated June 29, 2026, of Praxis Precision Medicines, Inc. and are in agreement with the statements contained in the second, third and fourth paragraphs. We have no basis to agree or disagree with other s... |
| 29 Jun 2026 |
8-K: Other Events
On June 29, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) notified the Company that it has extended by three months the review period for its New Drug Application ... |
| 22 Jun 2026 |
8-K: Other Events
On June 22, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (“BTD”) for elsunersen (PRAX-222), an antisense oligonucleotide for the treatment of sei... |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, Praxis Precision Medicines, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. The Company held its Annual Meeting to consider and vote on the three ... |
| 01 Jun 2026 |
8-K: Other Events
On June 1, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures (“FOS”). The POWER1 study in highly refractory patients wit... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic enc... |
| 14 Apr 2026 |
8-K: Other Events
On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration (the “FDA”) has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults.... |
| 06 Apr 2026 |
8-K: Other Events
Praxis Precision Medicines, Inc. (the “Company”) is providing the following business updates: |
| 19 Feb 2026 |
8-K: Results of Operations and Financial Condition
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) |
| 08 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 8, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced the appointment of Megan Sniecinski as Chief Operating Officer of the Company, effective January 1, 2026 (the “Effective Date”). |
| 07 Jan 2026 |
8-K: Other Events
Introductory. Praxis Precision Medicines, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 2,212,000 shares (the “Firm Shares”) ... |
| 06 Jan 2026 |
8-K: Results of Operations and Financial Condition
Praxis Precision Medicines, Inc. (the “Company”) is providing the following financial information. As of December 31, 2025, the Company’s cash, cash equivalents and marketable securities were approximately $925 million. |
| 29 Dec 2025 |
8-K: Other Events
On December 29, 2025, Praxis Precision Medicines, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (“BTD”) for ulixacaltamide for the treatment of patients with essent... |
| 11 Dec 2025 |
8-K: Other Events
On December 9, 2025, Praxis Precision Medicines, Inc. (the “Company”) announced the completion of a Type C meeting with the U.S. Food and Drug Administration (the “FDA”) and agreement to immediately convert the EMBRAVE3 registrational st... |
| 08 Dec 2025 |
8-K: Other Events
On December 4, 2025, Praxis Precision Medicines, Inc. (the “Company”) announced the successful completion of its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (the “FDA”), including receipt of writte... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025 |
Loading...